Everything below concerns dihexa. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | Derived from angiotensin IV and modified for stability. |
| Proposed mechanism | c-Met/HGF pathway activation | Described as an HGF mimetic in experimental systems. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Name usage varies by supplier and publication. |
| Regulatory status | Not approved as a drug | Sold as a research chemical in some markets. |
| Human trial data | Limited or absent | Most evidence comes from preclinical studies. |
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
American Bells - A guide to the species in subgenus Viorna American Clematis Society Clematis viorna images at bioimages.vanderbilt.edu Clematis virginiana images at bioimages.vanderbilt.edu International Clematis Society "Clematis" . The American Cyclopædia. 1879. The Clematis., one of the Flowers of Loveliness for 1838 with an illustration (Clematis) by Thomas Uwins combined with poetry (The Clematis) by Letitia Elizabeth Landon.
=== Views on golf === In July 2007, Player made statements at the Open Championship golf tournament about the use of performance-enhancing drugs in golf. He alleged that at least ten players were "taking something", citing human growth hormone, steroids and creatine as possible substances. Both the PGA Tour and European Tour were in the process of introducing random testing programmes at the time. In June 2016, in an interview with bunkered.co.uk, Player branded as "laughable" a report released by the R&A and USGA governing bodies which said that driving distance in golf was only increasing minimally. He warned of a "tsunami coming" due to the governing bodies' failure to address issues surrounding new golf technology. After the 2017 Alfred Dunhill Links Championship, Player reiterated these comments, taking to messaging service Twitter to say he was sad to see the Old Course at St Andrews "brought to her knees" after Ross Fisher broke the course record on a day of very low scoring during the final round.
Naturally occurring xenon (54Xe) consists of nine isotopes: seven stable isotopes and two very long-lived radioactive isotopes: double electron capture has been observed in 124Xe (half-life 1.1 ± 0.2stat ± 0.1sys×1022 years), and double beta decay in 136Xe (half-life 2.18 ×1021 years), which are among the longest measured half-lives of all nuclides. The isotopes 126Xe and 134Xe are also predicted to undergo double beta decay, but such decay processes have not been observed. Artificial unstable isotopes have been prepared from 108Xe to 150Xe, the longest-lived of which is 127Xe with a half-life of 36.342 days. All other nuclides have half-lives less than 12 days, most less than one hour. The shortest-lived isotope, 108Xe, has a half-life of 58 μs, and is the heaviest known nuclide with equal numbers of protons and neutrons. Of known isomers, the longest-lived is 131mXe with a half-life of 11.95 days, the second longest of all xenon's nuclides. 129Xe is produced by beta decay of natural or artificial 129I (half-life 16.1 million years); 131mXe, 133Xe, 133mXe, and 135Xe are some of the fission products of both 235U and 239Pu, so are used as indicators of nuclear explosions. The artificial isotope 135Xe is of considerable significance in the operation of nuclear fission reactors. 135Xe has a huge cross section for thermal neutrons, 2.65 million barns, so it acts as a neutron absorber or "poison" that can slow or stop the chain reaction after a period of operation.
=== Role in Cardiovascular Events === The nitric oxide (NO)-cyclic guanosine monophosphate (cGMP)-phosphodiesterase (PDE) pathway has become a target in developing treatments for heart failure. A deficit in cGMP levels has been associated with adverse cardiovascular outcomes, promoting factors like myocardial fibrosis, vasoconstriction, and inflammation, all of which accelerate heart failure progression. Some soluble guanylate cyclase (sGC) stimulators, have yielded promising outcomes in reducing cardiovascular events. Their effectiveness is thought to result from increased sensitivity of sGC to endogenous NO. Elevated plasma cGMP levels, regulated predominantly by natriuretic peptides (NP) rather than nitric oxide (NO), were found to correlate with a higher risk of heart failure, atherosclerotic cardiovascular disease, and coronary heart disease.
The revived Mannerist sphinx of the late 15th century is sometimes thought of as the "French sphinx". Her coiffed head is erect and she has the breasts of a young woman. Often she wears ear drops and pearls as ornaments. Her body is naturalistically rendered as a recumbent lioness. Such sphinxes were revived when the grottesche or "grotesque" decorations of the unearthed Domus Aurea of Nero were brought to light in late 15th-century Rome, and she was incorporated into the classical vocabulary of arabesque designs that spread throughout Europe in engravings during the 16th and 17th centuries. Sphinxes were included in the decoration of the loggia of the Vatican Palace by the workshop of Raphael (1515–20), which updated the vocabulary of the Roman grottesche. The first appearances of sphinxes in French art are in the School of Fontainebleau in the 1520s and 1530s and she continues into the Late Baroque style of the French Régence (1715–1723). From France, she spread throughout Europe, becoming a regular feature of the outdoors decorative sculpture of 18th-century palace gardens, as in the Upper Belvedere Palace in Vienna, Sanssouci Park in Potsdam, La Granja in Spain, Branicki Palace in Białystok, or the late Rococo examples in the grounds of the Portuguese Queluz National Palace (of perhaps the 1760s), with ruffs and clothed chests ending with a little cape.
Sources: en.wikipedia.org
In anatomy, the meninges (; sing. meninx ; from Ancient Greek μῆνινξ (mêninx) 'membrane') are protective membranes that cover the brain and spinal cord. In mammals, three meninges have been clearly identified: the dura mater, the arachnoid mater, and the pia mater. Each layer has its own molecularly distinct type of fibroblasts. The meninges act as a physical and immunological protective barrier for the brain and spinal cord, shielding the central nervous system (CNS) from injury. They anchor and support the tissues of the CNS, and provide containment for cerebrospinal fluid (CSF) and the arteries and veins that supply blood to the brain and spinal cord. The dura mater surrounds the arachnoid mater and supports the dural sinuses, which carry blood from the brain to the heart. The area between the arachnoid and pia mater is known as the subarachnoid space. It contains cerebrospinal fluid. The arachnoid and pia maters produce prostaglandin D2 synthase, a major cerebrospinal fluid protein. The arachnoid mater provides a restrictive permeability barrier between the cerebrospinal fluid in the subarachnoid space and the circulation of blood in the dura. The pia mater is a thin sheet of connective tissue that interfaces with the glial limitans superficialis.
=== Cancer === People with cancer undergoing chemotherapy are often given dexamethasone to counteract certain side effects of their antitumor treatments. Dexamethasone can increase the antiemetic effect of 5-HT3 receptor antagonists, such as ondansetron. The exact mechanism of this interaction is not well-defined, but it has been theorized that this effect may be due to, among many other causes, inhibition of prostaglandin synthesis, anti-inflammatory effects, immunosuppressive effects, decreased release of endogenous opioids, or a combination of the aforementioned. In brain tumors (primary or metastatic), dexamethasone is used to counteract the development of edema, which could eventually compress other brain structures. It is also given in cord compression, where a tumor is compressing the spinal cord. Evidence on the safety and efficacy of using dexamethasone to treat malignant brain tumors is not clear. Dexamethasone is also used as a direct chemotherapeutic agent in certain hematological malignancies, especially in the treatment of multiple myeloma, in which dexamethasone is given alone or in combination with other chemotherapeutic drugs, including most commonly with thalidomide (Thal-dex), lenalidomide, bortezomib (Velcade, Vel-dex), or a combination of doxorubicin (Adriamycin) and vincristine or bortezomib/lenalidomide/dexamethasone.
Rossman (1993), judge on the United States Court of Appeals for the Tenth Circuit Nancy Abudu (1996), lawyer and nominee to the United States Court of Appeals for the Eleventh Circuit Nusrat Jahan Choudhury (1998), lawyer and nominee to the United States District Court for the Eastern District of New York Roy Altman (2004), judge of the United States District Court for the Southern District of Florida Raph Graybill (2010), attorney, chief legal counsel to Steve Bullock and Democratic candidate in the 2020 Montana Attorney General election Shana Knizhnik (2010), lawyer and author known for her book Notorious R.B.G.: The Life and Times of Ruth Bader Ginsburg
== Mythological origins == In Greek mythology, the centaur Chiron was a "Wounded Healer", after being poisoned with an incurable wound by one of Hercules's arrows. Jung mentioned the Chiron myth "wounding by one's own arrow means, first of all, the state of introversion"; For Jung, "a good half of every treatment that probes at all deeply consists in the doctor's examining himself... it is his own hurt that gives a measure of his power to heal. This, and nothing else, is the meaning of the Greek myth of the wounded physician." Jung felt that depth psychology can be potentially dangerous, because the analyst is vulnerable to being infected by his analysis by having his own wounds reopened. To avoid this, the analyst must have an ongoing relationship with the unconscious, otherwise he or she could identify with the "healer archetype", and create an inflated ego. Withdrawal of both projections may however ultimately activate the powers of the inner healer in the patients themselves. Jung’s closest colleague, Marie Louise Von Franz, said “the wounded healer IS the archetype of the Self [our wholeness, the God within] and is at the bottom of all genuine healing procedures.” Jungians warn of the dangers of inflation and splitting in the helping professions, involving projection of the 'wounded' pole of the archetype onto the patient alone, with the analyst safely separated off as 'healer'.
Sources: en.wikipedia.org
The four main components of extremities are bones, vessels, nerves, and soft tissues. Gunshot wounds can thus cause severe bleeding, fractures, nerve deficits, and soft tissue damage. The Mangled Extremity Severity Score (MESS) is used to classify the severity of injury and evaluates for severity of skeletal and/or soft tissue injury, limb ischemia, shock, and age. Depending on the extent of injury, management can range from superficial wound care to limb amputation. Vital sign stability and vascular assessment are the most important determinants of management in extremity injuries. As with other traumatic cases, those with uncontrolled bleeding require immediate surgical intervention. If surgical intervention is not readily available and direct pressure is insufficient to control bleeding, tourniquets or direct clamping of visible vessels may be used temporarily to slow active bleeding. People with hard signs of vascular injury also require immediate surgical intervention. Hard signs include active bleeding, expanding or pulsatile hematoma, bruit/thrill, absent distal pulses and signs of extremity ischemia. For stable people without hard signs of vascular injury, an injured extremity index (IEI) should be calculated by comparing the blood pressure in the injured limb compared to an uninjured limb in order to further evaluate for potential vascular injury. If the IEI or clinical signs are suggestive of vascular injury, the person may undergo surgery or receive further imaging including CT angiography or conventional arteriography.
Since 1947, the Doomsday Clock of the Bulletin of the Atomic Scientists has visualized how close the world is to a nuclear war. The Doomsday Clock reached a high point in 1953, when the Clock was set to two minutes until midnight after the U.S. and the Soviet Union began testing hydrogen bombs, and in 2018, following the failure of world leaders to address tensions relating to nuclear weapons and climate change issues. Since 2026, the Clock has been set at 85 seconds to midnight, the closest it has ever been.
Galcanezumab, sold under the brand name Emgality, is a humanized monoclonal antibody used for the prevention of migraine. It is also used for the treatment of cluster headaches. A substance called calcitonin gene-related peptide (CGRP) has been shown to be involved in the development of migraine by widening blood vessels in the brain. Galcanezumab is a monoclonal antibody (a type of protein) designed to attach to and block CGRP, thereby helping blood vessels to return to their normal size. This will stop the symptoms of migraine. Galcanezumab is generally delivered through self-injections. Common side effects include injection site reactions such as pain or redness. Other side effects may include hypersensitivity reactions. Galcanezumab was developed by Eli Lilly. It was approved for medical use in the United States and in the European Union in 2018, becoming the third calcitonin gene-related peptide (CGRP) inhibitor to be approved by the US Food and Drug Administration (FDA).
Bisulfite sequencing (also known as bisulphite sequencing) is the use of bisulfite treatment of DNA before routine sequencing to determine the pattern of methylation. DNA methylation was the first discovered epigenetic mark, and remains the most studied. In animals it predominantly involves the addition of a methyl group to the carbon-5 position of cytosine residues of the dinucleotide CpG, and is implicated in repression of transcriptional activity. Treatment of DNA with bisulfite converts cytosine residues to uracil, but leaves 5-methylcytosine residues unaffected. Therefore, DNA that has been treated with bisulfite retains only methylated cytosines. Thus, bisulfite treatment introduces specific changes in the DNA sequence that depend on the methylation status of individual cytosine residues, yielding single-nucleotide resolution information about the methylation status of a segment of DNA. Various analyses can be performed on the altered sequence to retrieve this information. The objective of this analysis is therefore reduced to differentiating between single nucleotide polymorphisms (cytosines and thymidine) resulting from bisulfite conversion (Figure 1).
=== Animal nutrition === The Ajinomoto Group started an animal nutrition business in 1965 and subsequently established an international production and supply system for amino acids to be used in animal feed. Ajinomoto developed a lysine formula called AjiPro-L for lactating dairy cows, which allows the lysine to reach the intestine without decomposing in the stomach.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide derived from angiotensin IV and studied for effects on synaptic plasticity. It is often described as a hepatocyte growth factor mimetic. It is not an approved medication.
It is based on angiotensin IV, a naturally occurring peptide fragment, but dihexa itself is chemically modified and synthetic. The modifications aim to improve stability and activity compared with the parent fragment.
Laboratory studies have used cell-based assays and rodent models. These examine receptor signaling, dendritic spine changes, and behavioral tasks. Published human clinical trial data are lacking.
Dihexa has been proposed to act through HGF and c-Met signaling. This pathway is linked to synapse formation and cellular growth. Direct binding and the precise molecular step remain uncertain.